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Abstract
Amylin, a pancreatic peptide that readily crosses the blood brain barrier (BBB), and amyloid-beta peptide (Ab), the main
component of amyloid plaques and a major component of Alzheimer’s disease (AD) pathology in the brain, share several
features. These include having similar b-sheet secondary structures, binding to the same receptor, and being degraded by
the same protease. Thus, amylin may be associated with Ab, but the nature of their relationship remains unclear. In this
study, we used human samples to study the relationship between plasma amylin and Ab in the context of the
apolipoprotein E alleles (ApoE). We found that concentrations of Ab1-42 (P,0.0001) and Ab1-40 (P,0.0001) increased with
each quartile increase of amylin. Using multivariate regression analysis, the study sample showed that plasma amylin was
associated with Ab1-42 (b= +0.149, SE = 0.025, P,0.0001) and Ab1-40 (b= +0.034, SE = 0.016, P = 0.04) as an outcome after
adjusting for age, gender, ethnicity, ApoE4, BMI, diabetes, stroke, kidney function and lipid profile. This positive association
between amylin and Ab1-42 in plasma was found regardless of the ApoE genotype. In contrast, the relationship between
amylin and Ab1-40 in plasma seen in ApoE4 non-carriers disappeared in the presence of ApoE4. Using AD mouse models,
our recent study demonstrates that intraperitoneal (i.p.) injection of synthetic amylin enhances the removal of Ab from the
brain into blood, thus resulting in increased blood levels of both amylin and Ab. The positive association between amylin
and Ab, especially Ab1-42, in human blood samples is probably relevant to the findings in the AD mouse models. The
presence of ApoE4 may attenuate amylin’s capacity to remove Ab, especially Ab1-40, from the AD brain.
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Introduction
Amylin is a short peptide of 37 amino acids produced and
secreted by the pancreas. Amylin and amyloid-beta peptide (Ab),
the main component of amyloid plaques and a major component
of brain Alzheimer’s disease (AD) pathology, share several
features, including similar b-sheet secondary structures [1],
binding to the same amylin receptor [2], and being degraded by
the same protease insulin-degrading enzyme (IDE) [3–5]. They
appear to affect each other in complex ways. A recent study found
an accumulation of amylin amyloid in the cerebrovascular system
in the AD brain, resulting in impaired vascular functioning [6].
Amylin readily penetrates the blood brain barrier (BBB) [7,8] and
mediates important brain functions including inhibiting appetite
thereby improving glucose metabolism[9,10], relaxing cerebro-
vascular structure [11,12], and, in all likelihood, enhancing neural
regeneration [13]. High levels of Ab in the AD brain may block
amylin’s ability to bind to its receptor, thus hindering normal
amylin functions that are essential to the brain [10].
Our recent study using two AD mouse models demonstrates
another important function of amylin in the brain. Chronic
treatment with intraperitoneal (i.p.) injection of amylin or its
clinical analog, pramlintide, enhanced removal of Ab from the
brain and improved their cognitive impairment (submitted and
under review). Through efflux, Ab can pass through the BBB into
blood [14]. BBB dysfunction, decreased cerebral blood flow, and
impaired vascular clearance of Ab from the brain are all thought
to contribute to AD pathogenesis [15]. It is well known that the
concentration of Ab in blood is much lower than the concentration
of Ab in the brain [16], suggesting that only a small portion of Ab
in the brain can be removed from the brain. As Ab is a key
element of AD pathogenesis in the brain [17], if a drug or
substance like amylin or its analogs can enhance the removal of Ab
from the AD brain into the blood, it might prove an effective
treatment for the disease. The use of solanezumab is an example of
this treatment strategy. This immune drug that removes Ab from
the AD brain into blood has been shown to delay cognitive decline
in those in an early stage of AD [18].
In humans the relationship between amylin and Ab in plasma is
unclear. It will be important to determine whether this naturally
occurring peptide derived from the pancreas has any role in
regulating Ab in the brain. If our mouse finding indicating that
PLOS ONE | www.plosone.org 1 February 2014 | Volume 9 | Issue 2 | e88063
peripheral amylin passes through the BBB and removes Ab from
the brain is relevant to humans, we anticipate that amylin will be
positively associated with Ab in human plasma samples. Apolipo-
protein E4 (ApoE4) is the major risk factor for AD with late onset
[19]. The ApoE4 allele is associated with BBB damage [20], which
likely adversely affects removal of Ab from brain into blood. Using
a large, homebound elderly population we aimed to examine the
relationship between amylin and Ab in blood in the context of the
ApoE alleles.
Materials and Methods
Study Population and Recruitment
We studied a group of 1092 subjects, all of whom had
measurements of plasma amylin and Ab, as well as ApoE
genotyping as part of a population-based study, the Nutrition, Aging
and Memory in the Elderly (NAME) study [21]. Subjects included
homebound elderly clients who were enrolled in one of four
homecare agencies in the Boston area between 2002 and 2007.
Anyone receiving homecare services was registered with one of
these agencies if he/she lived in the city of Boston, had an annual
income ,$18,890, and needed homecare service. All homebound
elders aged 60 and older at each of the four agencies were invited
to participate in the study. All enrolled subjects gave written
informed consent. The protocol, consent form and consent
procedure were approved by the Institutional Review Boards of
Tufts University New England Medical Center and Boston
University School of Medicine. All the signed consent forms have
been kept and locked in the research area.
Eligibility for enrollment required that the participants spoke
English, were physically able to participate in the study home
visits, and had sufficient vision and hearing to read and hear the
content of the neuropsychological tests. Those with Mini-Mental
State Examination (MMSE) #10 or verbal IQ,75 were not
eligible to continue in the study. Of all eligible subjects, 66%
enrolled in the study, and gave informed consent [22]. The
subjects were screened for cognitive impairment using the Mini
Mental State Examination (MMSE) [23].
Measurements
Plasma Amylin and Ab. Fasting blood draws were conduct-
ed. Blood samples were centrifuged immediately following blood
draw to isolate plasma. We used ELISA assay to measure amylin
concentration in plasma according to the manufacture’s instruc-
tions (LINCO Research, St. Charles, Missouri). All samples were
assayed in duplicate and averaged to give final values.
To measure Ab a sandwich Ab ELISA was used, as described
previously [24]. Briefly, plates were coated with 2G3 (anti-Ab40)
and 21F12 (anti-Ab42) antibodies overnight at 4uC. Samples were
then loaded and incubated overnight at 4uC followed by
incubation with a biotinylated monoclonal anti-N terminus Ab
antibody (3D6B) for 2 hrs. Finally, streptavidin-conjugated alka-
line phosphatase (Promega, USA) was added and incubated, and
the signal was amplified by adding alkaline phosphatase fluores-
cent substrate (Promega, USA), which was then measured.
ApoE genotyping. A 244 bp fragment of the apoE gene
including the two polymorphic sites was amplified by PCR using a
robotic Thermal Cycler (ABI 877, Perkin-Elmer/Applied Biosys-
tems), using oligonucleotide primers F4 (59-ACAGAATT-
CGCCCCGGCCTGGTACAC-39) and F6 (59-TAAGCTTGG-
CACGGCTGTCCAAGGA-39). The PCR products were digest-
ed with 5 units of Hha I and the fragments separated by
electrophoresis on 8% polyacrylamide non-denaturing gel. The
specific allelic fragments were: E2; E3; and E4. ApoE4 was defined
by E4/4, E3/4 or E2/4 [25].
Other blood tests. Serum lipid profiles, including cholester-
ol, LDL and HDL, and serum creatinine, were measured by the
clinical laboratory according to the standard protocols at Jean
Mayer USDA Human Nutrition Research Center on Aging
(HNRCA), Tufts University.
Other Clinical Evaluation
Weight and height were measured twice using standardized
instruments for weight and height, and the average of two
measurements was used to calculate BMI (kg/m2). Diabetes was
defined by the use of anti-diabetic medication or fasting glucose
greater than 126 mg/dl, parameters widely used in population-
based studies [26]. Subjects were asked to show all the medications
they were taking, and research assistants documented the
medication names according to the labels.
Statistical Analysis
Statistical analysis was performed using SAS (version 9.1).
Normally distributed variables, such as age, were presented as
mean 6 SD and compared using t-tests for the ApoE4 subgroups
or using ANOVA test across the quartiles. Variables with skewed
distributions (plasma amylin, Ab1-42, Ab1-40, and Ab1-40/Ab1-
42 ratio) were presented as median (25th, 75th percentiles) and
compared using Wilcoxon rank sum test for ApoE4 subgroups or
using Kruskal-Wallis test across quartiles [24]. The Chi-Square
test was used to compare proportions for binary endpoints. Amylin
(LogAmylin), Ab1-42 (Log Ab1-42), and Ab1-40 (Log Ab1-40)
were transformed to log10 for multivariate regression due to
skewed distributions. Univariate and multivariate linear regression
were used to examine associations between Log Amylin and Log
Ab1-42 or Log Ab1-40 while adjusting for age, ApoE4,
depression, creatinine and other confounders. For all analyses,
the two-sided significance level of 0.05 was used.
Results
Study Population
From the completed NAME study, 1092 subjects with ApoE
genotyping and measurements of plasma amylin and Ab were
used for the study analysis (Table 1); 24% of them carried at least
one ApoE4 allele. The average age (mean 6 SD) of this study
sample was 75.068.0 years old, and 76% were female. The
population was multi-ethnic, with 61% Caucasian, 35% African
American and 4% other ethnicities. Most subjects (67%) had high
school education or above. The average BMI was 31.668.6, and
37% had a history of diabetes (Table 1). The distributions of all
amylin, Ab1-42 and Ab1-40 in plasma were skewed (Table 1). For
plasma amylin (pM/L): median = 22.3, Q1= 11.8, Q3= 40.0; for
Ab1-42 (pg/ml): median = 17.4, Q1= 11.8, Q3= 22.6, and for
Ab1-40 (pg/ml): median = 133.4, Q1= 99.5, Q3= 172.7.
We divided subjects into ApoE4 non-carriers (n = 834) and
ApoE4 carriers (n = 258) (Table 1). There were no differences in
demographic variables between the two ApoE subgroups with the
exception that African Americans were more likely to be ApoE4
carriers than ApoE4 non-carriers (48% vs. 31%, p= 0.03). There
were no differences in lipid profiles between the two ApoE4
subgroups. Compared to the ApoE4 non-carriers, ApoE4 carriers
had a slightly lower concentration of Ab1-42 in plasma (p= 0.03)
and a higher Ab1-40/Ab1-42 ratio (p = 0.007). There were no
differences in the concentrations of amylin and Ab1-40 in the
ApoE4 subgroups.
Amylin and Amyloid-Beta Peptides
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A Positive Relationship between Plasma Amylin and Ab
Using Spearman rank correlation analysis, the study sample
showed that amylin was positively and moderately associated with
Ab1-42 (r =+0.20, p,0.0001) and Ab1-40 (r = +0.12, p,0.0001)
in plasma (Table 1). Subjects were divided into quartiles based on
the concentration of plasma amylin (Table 2). In plasma with
increasing quartile of amylin the concentrations of Ab1-42
(p,0.0001) increased in a linear pattern; the concentrations of
Ab1-40 (p,0.0001) also increased, but in a non-linear pattern
with a U shape; and the ratios of Ab1-40/Ab1-42 (p,0.0001)
decreased in a linear pattern.
While there was no difference in age across the four amylin
quartiles, average BMI (p,0.0001), kidney function as assessed by
creatinine levels (p,0.0001), and the rate of diabetes (p,0.05) all
increased with increasing quartile of amylin (Table 3). Cholesterol
and LDL levels had a positive relationship with increasing 1st to
3rd quartile of amylin, but their levels were lower in the 4th quartile
of amylin, indicating a nonlinear relationship. HDL concentration
Table 1. General information and univariate correlations of amylin and Ab stratified by ApoE4 status.
All subjects ApoE4 Non-carriers ApoE4 Carriers
n=1092 n=834 n=258
General Information
Age, year, mean ± SD 75.068.0 75.268.5 74.368.4
Female, n/total (%) 831/1092 (76%) 628/834 (75%) 203/258 (79%)
African Americans, n/total (%) 383/1087 (35%) 258/829 (31%) 125/258 (48%)***
High School Graduate and above, n/total (%) 726/1086 (67%) 555/832 (67%) 171/254 (67%)
History of stroke, n/total (%) 216/1062 (20%) 170/813 (21%) 46/249 (18%)
BMI, mean ± SD 31.668.6 31.768.9 31.368.0
Diabetes, n/total (%) 387/1059 (37%) 293/810 (36%) 94/249 (38%)
Creatinin, mean ± SD 1.161.0 1.060.8 1.261.5
Cholesterol, mg/dL, Mean ± SD 184.9643.2 184.4643.5 187.0642.3
LDL, mg/dL, Mean ± SD 107.3635.9 106.4636.1 110.4635.4
HDL, mg/dL, Mean ± SD 49.6614.8 49.4615.0 50.4614.1
Amylin and Ab in Plasma
Amylin, pM/L, Median (Q1, Q3) 22.3 (11.8, 40.0) 20.4 (11.8, 38.7) 22.5 (11.5, 41.2)
Ab1- 42, pg/ml, Median (Q1, Q3) 17.4 (11.8, 22.6) 18.0 (12.2, 27.7) 17.1 (11.4, 23.5)*
Ab1- 40, pg/ml, Median (Q1, Q3) 133.4 (99.5, 172.7) 134.0 (99.7, 174.1) 135.2 (100.3, 183.8)
Ab1- 40/Ab1- 42 ratio, Median (Q1, Q3) 7.6 (4.9, 11.0) 7.4 (4.7, 10.7) 8.8 (5.3, 11.9)**
Univariate Spearman Correlations
Amylin with Ab1- 42 r = +0.20, p,0.0001 r =+0.21, p,0.0001 r = +0.22, p = 0.0003
Amylin with Ab1- 40 r = +0.12, p,0.0001 r =+0.15, p,0.0001 r = +0.04, p = 0.57
Mean 6 SD or n/total (%) and the comparisons between ApoE4 non-carriers and ApoE4 carriers are presented. P values for the statistical significance are shown.
*p = 0.03;
**p = 0.007;
***p,0.0001.
Univariate Spearman Correlations on the relationships between amylin and Ab are shown for the whole sample and the ApoE4 subgroups.
BMI = Body Mass Index; LDL = low density lipoprotein; HDL = high density lipoprotein.
doi:10.1371/journal.pone.0088063.t001
Table 2. Comparisons of Ab1-42, Ab1-40 and Ab1-40/Ab1-42 ratio across the amylin quartiles.
Amylin Quartiles Quartile 1 Quartile 2 Quartile 3 Quartile 4 P values
Ab1- 42, Median 16.0 16.3 17.1 21.4
(Q1, Q3) (11.4, 22.3) (11.4, 24.2) (12.2, 26.1) (13.7, 39.7) ,0.0001
Ab1- 40, Median 134.4 126.8 127.0 150.2
(Q1, Q3) (101.9, 176.1) (91.0, 166.8) (91.4, 160.5) (117.2, 160.5) ,0.0001
Ab1-40/Ab1- 42, Median 9.0 7.8 7.1 6.9
(Q1, Q3) (6.03, 12.6) (5.1, 11.2) (4.6, 10.3) (4.3, 10.0) ,0.0001
Median (Q1, Q3) is used to describe the distributions of plasma Ab1-42, Ab1-40 and the Ab1-40/Ab1-42 ratio. Using Kruskal-Wallis test, the comparisons are shown
across the amylin quartiles. P values for the statistical significance are shown.
doi:10.1371/journal.pone.0088063.t002
Amylin and Amyloid-Beta Peptides
PLOS ONE | www.plosone.org 3 February 2014 | Volume 9 | Issue 2 | e88063
was inversely associated with increasing quartile of amylin in
plasma (P,0.0001).
Because of their skewed distributions, amylin, Ab1-42 and Ab1-
40 were transformed to log10 for multivariate linear regression.
Using multivariate regression (Table 4), log10 of amylin remained
positively associated with both log10 of plasma Ab1-42
(b= +0.166, SE= 0.024, P,0.0001) and log10 of plasma Ab1-40
(b= +0.053, SE= 0.016, P= 0.001) respectively after adjusting for
age, gender, ethnicity, BMI and ApoE4 (Model I). After adding
kidney function as assessed by concentration of creatinine, log10 of
amylin was still associated with either log10 of plasma Ab1-42
(b= +0.150, SE= 0.024, P,0.0001) or log10 of plasma Ab1-40
(b= +0.031, SE= 0.016, P= 0.05) (Model II), but the relationships
were attenuated. Finally, the relationship between log10 of amylin
and either log10 of plasma Ab1-42 (b= +0.146, SE=0.025,
P,0.0001) or log10 of plasma Ab1-40 (b= +0.034, SE= 0.016,
P = 0.04) as an outcome persisted after adjusting for age, gender,
ethnicity, ApoE4, BMI, diabetes, stroke, creatinine and lipid
profile including cholesterol, LDL and HDL (Model III). Adding
education and MMSE to the model did not change the
relationships between amylin and Ab (data not shown). The
concentration of creatinine was positively associated with both
log10 of plasma Ab1-40 and log10 of plasma Ab1-42. ApoE4 was
negatively associated with plasma Ab1-42, but not with plasma
Ab1-40 in this model.
The Relationship between Amylin and Ab in the Context
of ApoE Allele
Subjects were divided into ApoE4 non-carriers and carriers
(Table 1). In the absence of ApoE4, the relationships between
amylin and Ab1-42 (b= +0.158, SE= 0.031, P,0.0001) or Ab1-
40 (b= +0.044, SE= 0.020, P= 0.03) in plasma still remained after
adjusting for age, gender, ethnicity, BMI, diabetes, stroke,
creatinine and the lipid profile (Tables 1 and 5). With increasing
quartile of amylin, the concentrations of Ab1-42 (p,0.0001)
(Figure 1A) and Ab1-40 (p,0.0001) (Figure 1C) increased in
plasma in ApoE4 non-carriers. Since increased amylin was more
associated with Ab1-42 than with Ab1-40, the ratio of Ab1-40/
Ab1-42 was decreased with increasing quartile of amylin in the
absence (median: Q1= 8.7; Q2= 7.7; Q3= 7.0 and Q4=6.6,
p = 0.0001).
In contrast to ApoE4 non-carriers, ApoE4 carriers had a
different pattern of the relationship between amylin and Ab. In the
presence of ApoE4, while the relationship between amylin and
Ab1-42 (b= +0.112, SE= 0.042, P= 0.008) remained but atten-
uated, the relationship between amylin and Ab1-40 disappeared
after adjusting for the confounders (Tables 1 and 5). In ApoE4
carriers, with increasing quartile of amylin, the concentrations of
Ab1-42 increased in plasma (p= 0.0004) (Figure 1B), but the
relationship between amylin quartiles and Ab1-40 in plasma was
weak and presented with a U shape (Figure 1D). The ratio of Ab1-
40/Ab1-42 was decreased with increasing quartile of amylin in the
presence of ApoE4 allele (median: Q1= 10.1; Q2=9.0; Q3= 8.5
and Q4=7.3, p = 0.006). ApoE4 carriers had a higher level of
Ab1-40/Ab1-42 ratio than ApoE4 non-carriers in amylin quartiles
1 and 3 with statistical significance (p,0.05).
Discussion
Our recent study using AD mouse models demonstrated that
i.p. injection of synthetic amylin or its analog, pramlintide,
enhanced the removal of Ab from the brain into blood (submitted
and under review). In light of this effect, we hypothesized that
Table 3. Comparisons of age, metabolic diseases and biomarkers across the amylin quartiles.
Amylin Quartiles Quartile 1 Quartile 2 Quartile 3 Quartile 4
Age, year, Mean ± SD 75.568.7 75.068.4 75.168.5 74.268.5
History of stroke, n/total (%) 54/265 (20%) 61/272 (22%) 53/270 (20%) 50/268 (19%)
BMI, Mean ± SD ** 30.068.4 31.469.0 32.067.6 32.969.1
Diabetes, n/total (%) * 97/265 (37%) 87/269 (32%) 92/268 (34%) 117/265 (44%)
Creatinine, mg/dL, Mean ± SD*** 0.9060.68 0.9360.92 1.0560.74 1.3961.53
Cholesterol, mg/dL, Mean ± SD ** 183.8646.3 183.8641.3 192.1643.9 179.0640.2
LDL, mg/dL, Mean ± SD ** 106.7638.1 108.1635.1 112.4635.6 100.9633.5
HDL, mg/dL, Mean ± SD *** 53.6616.6 49.3613.7 49.2614.7 46.6613.4
Mean6 SD with ANOVA test or n/total with Chi-Square test is used to describe the distributions and comparisons of age, diseases and the biomarkers across the amylin
quartiles.
*p#.05.
**p#.001,
***p#.0001 for the statistical significance are shown.
BMI = Body Mass Index; LDL = low density lipoprotein; HDL = high density lipoprotein.
doi:10.1371/journal.pone.0088063.t003
Table 4. Effects of amylin on Ab42 or Ab42 in plasma in
multivariate regression analyses.
Whole sample Log Ab1-42 Log Ab1-40
Estimate b (SE) P value Estimate b (SE) P value
Model I: Log
Amylin
+0.166 (0.024) ,0.0001 +0.053 (0.016) 0.001
Model II: Log
Amylin
+0.150 (0.024) ,0.0001 +0.031 (0.016) 0.05
Model III: Log
Amylin
+0.149 (0.025) ,0.0001 +0.034 (0.016) 0.04
Model I: adjusting for age, gender, ethnicity, BMI and ApoE4; n = 1000 for Ab1-
42; n = 1001 for Ab1-40.
Model II: Model I plus creatinine; n = 983 for Ab1-42; n = 984 for Ab1-40.
Model III: Model II plus diabetes, stroke, cholesterol, LDL and HDL; n = 951 for
Ab1-42; n = 952 for Ab1-40.
doi:10.1371/journal.pone.0088063.t004
Amylin and Amyloid-Beta Peptides
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endogenous amylin in blood would enhance the removal of Ab
from the brain, especially in elderly with amyloid pathology in the
brain. This would lead to a positive relationship between these two
peptides in blood. Our current human study did indeed show a
positive association between naturally occurring amylin and Ab in
plasma, likely due to a mechanism similar to that seen in the
mouse model. Thus it is possible that endogenous and synthetic
amylin have similar effects on Ab in the brain.
It is intriguing that amylin (Tables 2 and 3) and Ab, especially
Ab1-42, were positively associated in plasma, suggesting that
Figure 1. Characterization of Ab with increasing amylin quartiles. Subjects are divided into four quartiles based on the concentration of
amylin in plasma. Box plots were used to illustrate the median concentration with 25% (Q1) and 75% (Q3) range of plasma Ab. Plasma Ab1-42 (A and
B) and Ab1-40 (C and D) in the absence (A and C) and presence (B and D) of ApoE4 allele in quartile 1 (Q1), quartile 2 (Q2), quartile 3 (Q3) and quartile
4 (Q4) of plasma amylin are shown.
doi:10.1371/journal.pone.0088063.g001
Table 5. Effects of amylin on Ab42 or Ab42 in plasma in the absence and the presence of ApoE4 allele.
ApoE4 non-carriers Log Ab1-42 (n =746) Log Ab1-40 (n=746)
Estimate b (SE) P value Estimate b (SE) P value
Log Amylin +0.158 (0.031) ,0.0001 +0.044 (0.020) 0.03
ApoE4 carriers Log Ab1-42 (n =229) Log Ab1-40 (n=230)
Estimate b (SE) P value Estimate b (SE) P value
Log Amylin +0.112 (0.042) 0.008 20.001 (0.031) 0.98
Adjusted for age, gender, ethnicity, BMI, diabetes, stroke, creatinine, cholesterol, LDL and HDL for the ApoE subgroups.
doi:10.1371/journal.pone.0088063.t005
Amylin and Amyloid-Beta Peptides
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naturally occurring amylin may also enhance removal of Ab from
the brain. In general, a positive association between two peptides
in a compartment in the body can occur by three mechanisms, e.g.
1) co-production/co-secretion, 2) competitive degradation/clear-
ance, or 3) one peptide moving another to the same location. It is
logical to anticipate that if two molecules do not encounter each
other in the same tissue regions, they generally will not compete
for the same protease degradation or bind the same receptor to be
cleared or influence each other, and thus will not have a positive
association. Although amylin is a peripheral peptide produced and
secreted by the pancreas and Ab occurs primarily in the brain,
especially the AD brain [16], amylin does readily cross the BBB
[7,8] and thus amylin and Ab may therefore encounter each other
in the brain. Another pancreatic peptide, insulin, is much less
likely than amylin to be transported into the brain via the BBB
[7,8]. It is not surprising that in the same plasma samples we did
not find any association between insulin and Ab (data not shown).
Note that when using cell cultures, insulin and Ab encounter each
other in the cell media and a significantly positive relationship
between insulin and Ab is observed [3–5].
Amylin levels were inversely associated with the Ab1-40/Ab1-
42 ratio in plasma (Table 2 and Figure 1). Two large, prospective
population studies have shown that a high plasma Ab40/Ab42
ratio, determined by both low Ab42 and high Ab40, increases the
risk of AD [27,28]. While Ab42 is a major component of AD
pathology in the brain [29], Ab40 is a component of cerebral
amyloid angiopathy (CAA) [30]. High levels of plasma Ab40 are
associated with cerebral microvascular pathology, white matter
hyperintensities (WHI) and lacunar infarcts [31,32]. The plasma
Ab42 decline seen in the pre-clinical stage of AD [33,34],
indicating the formation of AD pathology. Thus a high Ab40/
Ab42 ratio in plasma may be a biomarker of cerebral microvas-
cular pathology, which is associated with high plasma Ab40, co-
existing AD pathology, which is associated with low plasma Ab42.
Since plasma amylin levels were found to be inversely associated
with Ab40/Ab42 ratio, it is possible that higher plasma amylin is a
protecting factor for the development of AD.
ApoE4 is a major risk factor for late-onset AD as well as for
cerebrovascular disease [35]. The positive association between
amylin and Ab1-40in blood disappeared in the presence of ApoE4
(Table 5). Although the effect of ApoE4 on the relationship
between amylin and Ab is unknown, we hypothesized that ApoE4
may attenuate amylin’s activity in removing Ab, especially Ab40,
out of the brain via the BBB. Ab40 is the primary peptide that is
deposited in the cerebrovasculature of the AD brain under the
influence of the ApoE4 allele [36]. BBB dysfunction, decreased
cerebral blood flow, and impaired vascular clearance of Ab from
brain are all thought to contribute to AD pathogenesis [15].
Amylin has been shown to have a vasorelaxant effect [37] that
may result in enhanced removal of Ab from the brain. A recent
study found an accumulation of amylin amyloid in the
cerebrovasculature of the AD brain [6]; the resulting microvas-
cular dysfunction may interfere with amylin’s ability to relax
cerebrovasculature. Since some ApoE4 carriers do not develop
AD even at a great age [38], other factors, such as amylin, may
interact with ApoE4 to influence AD development.
High plasma levels of amylin were associated with obesity and
type 2 diabetes, as well as with other biomarkers of metabolic
syndrome and cerebrovascular disease including low HDL levels,
high creatinine levels, and non-linear increased levels of choles-
terol and LDL (Table 2). These data suggest a relationship
between amylin resistance, obesity, and type 2 diabetes, which is
consistent with findings in other studies [39] [40] [41,42]. Amylin
was independently associated with Ab even after adjusting for
these biomarkers of metabolic syndrome (Table 3). Since amylin is
cleared by the kidney [43], the relationship between plasma
amylin and Ab, especially Ab1-40, was influenced by adding
creatinine to the models.
Amylin’s major role in the brain is to reduce food intake thereby
controlling body weight and regulating glucose metabolism [44].
Administering exogenous amylin, either peripherally or intracer-
ebroventricularly, results in reduced appetite and food intake [8].
Pramlintide, an amylin analog differing by three amino acids, is an
effective and well-tolerated drug in clinical use for the treatment of
diabetes [45] [46]. Given the effectiveness of the amylin class of
peptides in reducing amyloid pathology in the brain in the
preclinical study and the relationship between amylin and Ab in
the context of ApoE allele seen in this human study, pramlintide
may have potential as a treatment in AD. A clinical trial of
pramlintide in AD, an off-label use, may be warranted.
Limitations of our study are its cross-sectional design and lack of
brain imaging. Longitudinal studies are needed to confirm the
causal relationship between high levels of plasma amylin and
decreased Abdeposition in the brain. There were no diagnoses of
AD and mild cognitive impairment (MCI) for this population
based study. Future studies are necessary to examine the
concentrations of amylin and its relationship to Ab in specific
diagnostic groups.
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